title: Chemoimmunotherapy with bendamustine hydrochloride and alemtuzumab demonstrates synergism in T-prolymphocytic leukemia.
authors.affiliation: Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore.
authors.forename: Hao Xiang
authors.initials: HX
authors.lastname: Yong
authors.forename: Yeh Ching
authors.initials: YC
authors.lastname: Linn
authors.forename: Kiat Hoe
authors.initials: KH
authors.lastname: Ong
authors.forename: Daryl
authors.initials: D
authors.lastname: Tan
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000069461:Bendamustine Hydrochloride; D003131:Combined Modality Therapy; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D015461:Leukemia, Prolymphocytic, T-Cell / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage*; D014407:Tumor Cells, Cultured
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D009588:Nitrogen Mustard Compounds; D000074323:Alemtuzumab; D000069461:Bendamustine Hydrochloride